Archives

Brenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting

B BOSTON, April 16, 2026 /PRNewswire/ —  Brenig Therapeutics Inc. (Brenig), a clinical-stage biotechnology company developing brain-penetrant small molecule therapies for neurodegenerative diseases, today announced that data from its ongoing…

Read MoreBrenig Therapeutics to Present Phase 1 Data for BT-267 at the American Academy of Neurology (AAN) 2026 Annual Meeting

Mega Matrix Announces Fiscal 2025 Annual Results on Form 20-F: Dual-Engine Strategy Delivers Operational Efficiency, Margin Improvement and Strategic Web3 Growth

B SINGAPORE, April 16, 2026 /PRNewswire/ — Mega Matrix Inc. (“MPU” or the “Company”) (NYSE American: MPU), a global short-drama streaming platform operator and digital asset treasury strategy company, today…

Read MoreMega Matrix Announces Fiscal 2025 Annual Results on Form 20-F: Dual-Engine Strategy Delivers Operational Efficiency, Margin Improvement and Strategic Web3 Growth